SURVYR

NTLA

Intellia Therapeutics, Inc.
$12.28
+$1.02 (9.06%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-46%-30%-13%+4%+21%Oct 2025Oct 2026Apr 202652w low $7.95
NTLASPY
Wall St. Highest PT $61.00 (+396.7%) Wall St. Avg PT $23.11 (+88.2%)
$8$24$39$54$70POC $13Hi $61Avg $23
Underwater Drawdown %Max DD -45.6%Current -31.2%
0.0%-45.6%
Relative Strength vs SPY-30.5% vs SPYUnderperforming
+51%0%-51%
1W
+$0.44 (3.72%)
1M
+$0.53 (4.51%)
3M
+$1.39 (12.76%)
6M
−$0.92 (6.97%)
YTD
+$3.29 (36.60%)
1Y
−$2.51 (16.97%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
18 analysts · mean score 2.35
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$12.28
Average target$23.11
+$10.83 (+88.2%) upsideaverage target vs current price
CurrentAverageMedian
Low$8.00
Median$23.11
High$61.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.6B
P/E (next 12 months, estimated)-4.5
52-week range$7.95 – $26.90
Revenue growth (latest quarter vs a year ago)-46.2%
Dividend yieldNo dividend
Analyst consensusBuy (18)
Average analyst price target$23.11 (+88%)

What they do

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for NTLA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

NTLA earningsNext report in 9 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus-$0.79
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.80est -$0.78−1.9%Below estimates
May 11, 2026-$0.81est -$0.90+9.8%Above estimates
Feb 26, 2026-$0.83est -$0.96+13.7%Above estimates
Nov 6, 2025-$0.92est -$0.98+6.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 18:45:56 ET
24-1125-0225-0525-0825-1126-0226-0526-08-1.370.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.
Insider trades
Dube Michael P
VP, Chief Accounting Officer · 2026-10-02
Sell
$23.2K
Leonard John M
Director, President and CEO · 2026-08-21
Sell
$36.2K
Leonard John M
Director, President and CEO · 2026-08-20
Sell
$250.6K
Dulac Edward J Iii
EVP, Chief Financial Officer · 2026-07-22
Sell
$91.2K

Stats refreshed 2026-10-26 18:45:56 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026